Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 13,334 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Janux Therapeutics Trading Up 1.3 %

Shares of JANX traded up $0.68 during mid-day trading on Friday, reaching $53.92. 662,337 shares of the stock traded hands, compared to its average volume of 802,119. Janux Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $71.71. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -46.09 and a beta of 3.29. The firm has a fifty day moving average price of $54.52 and a 200 day moving average price of $47.73.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s quarterly revenue was down 82.6% on a year-over-year basis. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in Janux Therapeutics in the third quarter worth $4,943,000. Algert Global LLC bought a new position in Janux Therapeutics in the third quarter valued at $1,112,000. FMR LLC increased its stake in Janux Therapeutics by 0.6% in the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after acquiring an additional 47,075 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Janux Therapeutics during the third quarter valued at about $940,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JANX has been the topic of several research analyst reports. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Scotiabank increased their price target on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. UBS Group assumed coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price for the company. Finally, Stifel Nicolaus lifted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.